Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,marketState,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,exchange,priceHint,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Apr 29, 2021) 4","Short Ratio (Apr 29, 2021) 4","Short % of Float (Apr 29, 2021) 4","Short % of Shares Outstanding (Apr 29, 2021) 4","Shares Short (prior month Mar 30, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,ISEE,167188000.0,90169600,,,-26795000,,-26795000,8322000,-18549000,-26871000,-26871000,,,,,,0,0,26871000,18549000,76000,,-26795000,-26795000,758964000.0,20214000.0,167188000.0,187402000.0,90000.0,-591868000.0,2000.0,2000.0,29335000.0,20163000.0,2000.0,124000.0,187276000.0,150866000.0,1765000.0,6976000.0,-7710000,-5816000,-7710000,129000,454000,129000,-37038000,-29457000,13000,2687000,167113000.0,en-US,US,EQUITY,True,Delayed Quote,-1.1352875,10.3 - 10.73,10.57,0.0,0.0,40,40,finmb_36274487,NasdaqGS,"IVERIC bio, Inc.",USD,1865715,1615742,6.23,1.4763033,4.22 - 10.8,-0.35000038,-0.032407444,4.22,10.8,1620217800,1620217800,1620217800,-14400000,False,False,USD,PRE,-1.14,-0.86,-1.04,-10.048078,2.126,9.412571,1.0374289,0.11021738,7.2868476,3.1631522,0.4340906,942272320,-12.151162,4.915334,15,America/New_York,EDT,"IVERIC bio, Inc.",10.45,1630526403,-0.119999886,10.64,10.73,10.3,1308092,0,NMS,2,us_market,1.69,,,10.8,4.22,9.41,7.29,1.87M,1.62M,90.17M,,59.2M,0.84%,93.51%,5.23M,13.76,5.83%,5.80%,5.29M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-39.94%,-70.83%,,,,-62.78M,-96.74M,-96.27M,-1.14,,180.2M,2,106k,0.06,9.29,2.13,-78.03M,-42.96M,Value,10001,Healthcare,65,5,2,"IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was incorporated in 2007 and is based in New York, New York.",New York,212 845 8200,NY,7,1609372800,1619740800,6,United States,http://ivericbio.com,86400,6,Five Penn Plaza,212 845 8250,Biotechnology,Suite 2372
t-1,ISEE,191563000.0,90169600,,,-25432000,,-25432000,8022000,-17473000,-25495000,-25495000,,,,,,0,0,25495000,17473000,63000,,-25432000,-25432000,756543000.0,25191000.0,191563000.0,216754000.0,90000.0,-565073000.0,3000.0,5000.0,66373000.0,25130000.0,3000.0,146000.0,216603000.0,143674000.0,1765000.0,12792000.0,-35505000,5780000,-35505000,128000,-4078000,128000,-56446000,-21069000,35000,2626000,191473000.0,en-US,US,EQUITY,True,Delayed Quote,-1.1352875,10.3 - 10.73,10.57,0.0,0.0,40,40,finmb_36274487,NasdaqGS,"IVERIC bio, Inc.",USD,1865715,1615742,6.23,1.4763033,4.22 - 10.8,-0.35000038,-0.032407444,4.22,10.8,1620217800,1620217800,1620217800,-14400000,False,False,USD,PRE,-1.14,-0.86,-1.04,-10.048078,2.126,9.412571,1.0374289,0.11021738,7.2868476,3.1631522,0.4340906,942272320,-12.151162,4.915334,15,America/New_York,EDT,"IVERIC bio, Inc.",10.45,1630526403,-0.119999886,10.64,10.73,10.3,1308092,0,NMS,2,us_market,1.69,,,10.8,4.22,9.41,7.29,1.87M,1.62M,90.17M,,59.2M,0.84%,93.51%,5.23M,13.76,5.83%,5.80%,5.29M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-39.94%,-70.83%,,,,-62.78M,-96.74M,-96.27M,-1.14,,180.2M,2,106k,0.06,9.29,2.13,-78.03M,-42.96M,Value,10001,Healthcare,65,5,2,"IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was incorporated in 2007 and is based in New York, New York.",New York,212 845 8200,NY,7,1609372800,1619740800,6,United States,http://ivericbio.com,86400,6,Five Penn Plaza,212 845 8250,Biotechnology,Suite 2372
t-2,ISEE,214586000.0,90169600,,,-25450000,,-25450000,6643000,-18841000,-25484000,-25484000,,,,,,0,0,25484000,18841000,34000,,-25450000,-25450000,754136000.0,20009000.0,214586000.0,234595000.0,90000.0,-539641000.0,1000.0,,122819000.0,19933000.0,1000.0,196000.0,234399000.0,108303000.0,1764000.0,7012000.0,-108305000,2378000,-108305000,147000,6321000,147000,-122916000,-14758000,31000,1962000,214466000.0,en-US,US,EQUITY,True,Delayed Quote,-1.1352875,10.3 - 10.73,10.57,0.0,0.0,40,40,finmb_36274487,NasdaqGS,"IVERIC bio, Inc.",USD,1865715,1615742,6.23,1.4763033,4.22 - 10.8,-0.35000038,-0.032407444,4.22,10.8,1620217800,1620217800,1620217800,-14400000,False,False,USD,PRE,-1.14,-0.86,-1.04,-10.048078,2.126,9.412571,1.0374289,0.11021738,7.2868476,3.1631522,0.4340906,942272320,-12.151162,4.915334,15,America/New_York,EDT,"IVERIC bio, Inc.",10.45,1630526403,-0.119999886,10.64,10.73,10.3,1308092,0,NMS,2,us_market,1.69,,,10.8,4.22,9.41,7.29,1.87M,1.62M,90.17M,,59.2M,0.84%,93.51%,5.23M,13.76,5.83%,5.80%,5.29M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-39.94%,-70.83%,,,,-62.78M,-96.74M,-96.27M,-1.14,,180.2M,2,106k,0.06,9.29,2.13,-78.03M,-42.96M,Value,10001,Healthcare,65,5,2,"IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was incorporated in 2007 and is based in New York, New York.",New York,212 845 8200,NY,7,1609372800,1619740800,6,United States,http://ivericbio.com,86400,6,Five Penn Plaza,212 845 8250,Biotechnology,Suite 2372
t-3,ISEE,238041000.0,90169600,,,-18975000,,-18589000,6289000,-12720000,-19009000,-19009000,,,,,,-386000,0,19009000,12720000,34000,,-18589000,-18589000,752143000.0,11909000.0,238041000.0,249950000.0,89000.0,-514191000.0,,12000.0,245735000.0,11818000.0,,241000.0,249697000.0,,1764000.0,4634000.0,-108305000,2259000,-108305000,150127000,-1268000,150127000,137383000,-12744000,39000,1873000,237879000.0,en-US,US,EQUITY,True,Delayed Quote,-1.1352875,10.3 - 10.73,10.57,0.0,0.0,40,40,finmb_36274487,NasdaqGS,"IVERIC bio, Inc.",USD,1865715,1615742,6.23,1.4763033,4.22 - 10.8,-0.35000038,-0.032407444,4.22,10.8,1620217800,1620217800,1620217800,-14400000,False,False,USD,PRE,-1.14,-0.86,-1.04,-10.048078,2.126,9.412571,1.0374289,0.11021738,7.2868476,3.1631522,0.4340906,942272320,-12.151162,4.915334,15,America/New_York,EDT,"IVERIC bio, Inc.",10.45,1630526403,-0.119999886,10.64,10.73,10.3,1308092,0,NMS,2,us_market,1.69,,,10.8,4.22,9.41,7.29,1.87M,1.62M,90.17M,,59.2M,0.84%,93.51%,5.23M,13.76,5.83%,5.80%,5.29M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-39.94%,-70.83%,,,,-62.78M,-96.74M,-96.27M,-1.14,,180.2M,2,106k,0.06,9.29,2.13,-78.03M,-42.96M,Value,10001,Healthcare,65,5,2,"IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was incorporated in 2007 and is based in New York, New York.",New York,212 845 8200,NY,7,1609372800,1619740800,6,United States,http://ivericbio.com,86400,6,Five Penn Plaza,212 845 8250,Biotechnology,Suite 2372
